In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?

被引:18
|
作者
Kulkarni, Smita Chinmay [1 ]
Sundaram, Palaniswamy Shanmuga [1 ]
Padma, Subramanyam [1 ]
机构
[1] Amrita Vishwavidyapeetham, Dept Nucl Med & Mol Imaging, Amrita Inst Med Sci, Kochi, Kerala, India
关键词
Gallium-68 prostate-specific membrane antigen; positron emission tomography-computed tomography; prostate neoplasm; prostate-specific antigen; magnetic resonance imaging; ACCURACY; NODES; MRI; CT;
D O I
10.1097/MNM.0000000000001110
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective To assess the diagnostic performance of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography (Ga-68-PSMA PET-CT) in primary lymphnodal staging of patients with intermediate-risk and high-risk prostate cancer and to compare it with multiparametric MRI (mp-MRI) whenever available. Materials and methods Ga-68-PSMA PET-CT scans of 51 patients (average age 66.0 +/- 7.0 years) with biopsy-proven intermediate-risk and high-risk prostatic cancer who were managed by radical prostatectomy and extended pelvic lymph nodal dissection were retrospectively analyzed. Diagnostic performance of Ga-68-PSMA PET-CT in primary lymph nodal staging was analyzed using histopathology as reference. Diagnostic performance of mp-MRI, which was available in 35/51 patients was compared with that of Ga-68-PSMA PET-CT. Results Univariate analysis of patient characteristics showed significant influence of the pathological T-stage and maximum standard uptake value (SUV)max of the primary lesion on presence of nodal metastasis. In 51 patients, for patient-based analysis, the sensitivity, specificity and accuracy of Ga-68-PSMA PET-CT in detecting lymphnodal metastases were 80, 90.3 and 86.3%, respectively, and for lesion-based analysis 69.2, 99.6 and 98.4%, respectively. In 35/51 patients (who also had undergone mp-MRI), the patient-based and lesion-based sensitivity, specificity, and accuracy of Ga-68-PSMA PET-CT were 81.3, 84.2, 82.8% and 70.9, 99.5, 98.2%, respectively, and that of mp-MRI were 43.7, 78.9, 62.8% and 32.2, 98.5, 95.5%, respectively. For lesion-based analysis, Ga-68-PSMA PET-CT performed better than mp-MRI (P value = 0.04). Conclusion Ga-68-PSMA PET-CT allows accurate detection of lymphnodal metastases in patients with intermediate-risk and high-risk prostate cancer prior to definitive surgical treatment. It performed better than mp-MRI in a subset of patients.
引用
收藏
页码:139 / 146
页数:8
相关论文
共 50 条
  • [31] Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer
    Murphy, Declan G.
    Hofman, Michael
    Lawrentschuk, Nathan
    Maurer, Tobias
    BJU INTERNATIONAL, 2017, 119 (02) : 194 - 195
  • [32] Prognostic Role of Interleukin-23 in Prostate Adenocarcinoma: Comparison with Gallium-68 Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Computed Tomography Findings
    Gundogan, Cihan
    Ergul, Nurhan
    Serin, Huriye
    Beyhan, Ediz
    Yilmaz, Burcak
    Cermik, Tevfik Fikret
    ISTANBUL MEDICAL JOURNAL, 2021, 22 (04): : 320 - 325
  • [33] Re: Performance of a Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-derived Risk-stratification Tool for High-risk and Very High-risk Prostate Cancer
    Bjartell, Anders
    EUROPEAN UROLOGY, 2022, 82 (01) : 145 - 146
  • [34] 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review
    Corfield, Julia
    Perera, Marlon
    Bolton, Damien
    Lawrentschuk, Nathan
    WORLD JOURNAL OF UROLOGY, 2018, 36 (04) : 519 - 527
  • [35] 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review
    Julia Corfield
    Marlon Perera
    Damien Bolton
    Nathan Lawrentschuk
    World Journal of Urology, 2018, 36 : 519 - 527
  • [36] 18Fluorine Prostate-specific Membrane Antigen 1007 Positron Emission Tomography for High-risk Prostate Cancer
    Froehner, Michael
    Goerner, Matthias
    Merkle, Lennart
    Kopka, Klaus
    Zoephel, Klaus
    UROLOGY, 2024, 187 : 96 - 97
  • [37] 68-gallium Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Detects Rare Testicular Metastasis from Prostate Cancer
    Jain, Yash
    Agrawal, Archi
    Bakshi, Ganesh
    Joshi, Amit
    Menon, Santosh
    Prakash, Gagan
    Purandare, Nilendu
    Puranik, Ameya
    Shah, Sneha
    Rangarajan, Venkatesh
    INDIAN JOURNAL OF NUCLEAR MEDICINE, 2021, 36 (02): : 229 - 230
  • [38] Microcosting Study of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Prostate Cancer
    Parkinson, Bonny
    Sharma, Rajan
    Jeet, Varinder
    Song, Rachel
    Hoyle, Martin
    VALUE IN HEALTH REGIONAL ISSUES, 2022, 32 : 17 - 22
  • [39] Localization and restaging of carcinoma prostate by 68Gallium prostate-specific membrane antigen positron emission tomography computed tomography in patients with biochemical recurrence
    Seniaray, Nikhil
    Verma, Ritu
    Khanna, Sudhir
    Belho, Ethel
    Pruthi, Ankur
    Mahajan, Harsh
    INDIAN JOURNAL OF UROLOGY, 2020, 36 (03) : 191 - 199
  • [40] Upcoming Role of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Detecting Occult Metastases in Prostate Cancer
    Gupta, Parul
    Mishra, Rohini
    Gupta, Manoj
    Choudhury, Partha Sarthi
    INDIAN JOURNAL OF NUCLEAR MEDICINE, 2019, 34 (03): : 213 - 215